Related Experiment Video

Updated: Aug 2, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.9K

Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential

Brooke E Wilson1,2, Qiang Shen3, David W Cescon4

  • 1Department of Oncology, Queen's University, Kingston, ON, Canada.

Frontiers in Genetics
|April 17, 2023
PubMed

Insights

Triple negative breast cancer (TNBC) shows poor prognosis. Combining IL-1β inhibition with immunotherapy may improve treatment responses in TNBC patients.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Triple negative breast cancer (TNBC) presents a significant clinical challenge due to its poor prognosis compared to other breast cancer subtypes.
  • Current immunotherapies show limited efficacy in TNBC, necessitating novel strategies to enhance treatment outcomes.
  • The tumor immune microenvironment plays a critical role in TNBC progression and response to therapy.

Purpose of the Study:

  • To review phase III clinical trial data on immunotherapy for TNBC.
  • To explore the role of Interleukin-1 beta (IL-1β) in TNBC tumorigenesis and its potential as a therapeutic target.
  • To discuss the rationale for combining IL-1β inhibition with immunotherapy for TNBC treatment.

Main Methods:

  • Systematic review of published phase III clinical trial data for immunotherapy in TNBC.
  • Literature review of pre-clinical studies investigating the role of IL-1β in breast cancer.
  • Analysis of ongoing clinical trials involving IL-1β inhibitors in various cancers.

Main Results:

  • Immunotherapy has not achieved the same success in TNBC as in other solid tumors.
  • Pre-clinical evidence suggests IL-1β inhibition could be a viable strategy for TNBC.
  • Several trials are evaluating IL-1β inhibitors in breast cancer and other malignancies.

Conclusions:

  • There is a critical need for improved therapeutic strategies for TNBC.
  • Targeting IL-1β presents a promising avenue to enhance immunotherapy efficacy in TNBC.
  • Future research should focus on combining IL-1β inhibition with immunotherapy in both neoadjuvant and metastatic settings for TNBC.
Keywords:
IL1betaimmunotherapyinflammasometriple negative breast cancertumor microenvironment

More Related Videos

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.1K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
187
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
596
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
161